Cargando…
MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma
The efficacy of immune checkpoint blockade (ICB) therapy depends on sufficient infiltration and activation of primed tumor-specific cytotoxic T lymphocytes (CTLs) in the tumor microenvironment. However, many tumor types, including osteosarcoma, mainly display immune-desert or immune-excluded phenoty...
Autores principales: | Jiang, Kuo, Zhang, Qianfeng, Fan, Yong, Li, Jia, Zhang, Jitao, Wang, Wentao, Fan, Jinzhu, Guo, Yunshan, Liu, Shichang, Hao, Dingjun, Wang, Yongxiang, Wang, Lei, Shan, Lequn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924240/ https://www.ncbi.nlm.nih.gov/pubmed/35292660 http://dx.doi.org/10.1038/s41420-022-00923-8 |
Ejemplares similares
-
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
por: Kashyap, Abhishek S., et al.
Publicado: (2020) -
CD40–CD40L in Neurological Disease
por: Ots, Heather D., et al.
Publicado: (2022) -
Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils
por: Zhou, Aina, et al.
Publicado: (2023) -
RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse
por: Chen, Yizhi, et al.
Publicado: (2023) -
Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)